PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy. (Q44585456)

From Wikidata

Jump to navigation Jump to search

scientific article published on 29 June 2012

Language	Label	Description	Also known as
English	PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy.	scientific article published on 29 June 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22744290%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22744290%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference

based on heuristic

inferred from title

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22744290%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

author name string

Mattia Barbareschi

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22744290%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Lucia Veronica Cuorvo

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22744290%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Salvatore Girlando

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22744290%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Emma Bragantini

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22744290%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Elena Leonardi

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22744290%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Antonella Ferro

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22744290%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Alessia Caldara

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22744290%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Renza Triolo

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22744290%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Chiara Cantaloni

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22744290%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Nicola Decarli

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22744290%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Enzo Galligioni

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22744290%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Paolo Dalla Palma

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22744290%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

publication date

29 June 2012

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22744290%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Virchows Archiv

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22744290%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

461

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22744290%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22744290%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

129-139

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22744290%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Trastuzumab--mechanism of action and use in clinical practice

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1267-2

21 January 2018

Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1267-2

21 January 2018

Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1267-2

21 January 2018

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1267-2

21 January 2018

PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1267-2

21 January 2018

PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression.

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1267-2

21 January 2018

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1267-2

21 January 2018

Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas.

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1267-2

21 January 2018

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1267-2

21 January 2018

PIK3CA mutations in breast cancer are associated with poor outcome

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1267-2

21 January 2018

PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1267-2

21 January 2018

PIK3CA cancer mutations display gender and tissue specificity patterns.

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1267-2

21 January 2018

PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1267-2

21 January 2018

PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1267-2

21 January 2018

EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1267-2

21 January 2018

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1267-2

21 January 2018

The PIK3CA gene is mutated with high frequency in human breast cancers.

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1267-2

21 January 2018

PIK3CA in breast carcinoma: a mutational analysis of sporadic and hereditary cases

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1267-2

21 January 2018

Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1267-2

21 January 2018

PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1267-2

21 January 2018

Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1267-2

21 January 2018

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1267-2

21 January 2018

Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1267-2

21 January 2018

ABI3 ectopic expression reduces in vitro and in vivo cell growth properties while inducing senescence

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1267-2

21 January 2018

The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells.

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1267-2

21 January 2018

Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1267-2

21 January 2018

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1267-2

21 January 2018

Diagnostic value of automated Her2 evaluation in breast cancer: a study on 272 equivocal (score 2+) Her2 immunoreactive cases using an FDA approved system.

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1267-2

21 January 2018

Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1267-2

21 January 2018

Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency.

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1267-2

21 January 2018

The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1267-2

21 January 2018

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers

1 reference

https://api.crossref.org/works/10.1007%2FS00428-012-1267-2

21 January 2018

Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast

1 reference

https://pubmed.ncbi.nlm.nih.gov/22744290

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/22744290

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes

1 reference

https://pubmed.ncbi.nlm.nih.gov/22744290

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action

1 reference

https://pubmed.ncbi.nlm.nih.gov/22744290

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantitative growth fraction evaluation with MIB1 and Ki67 antibodies in breast carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/22744290

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/22744290

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytoplasmic p21WAF1/CIP1 correlates with Akt activation and poor response to tamoxifen in breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22744290

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib

1 reference

https://pubmed.ncbi.nlm.nih.gov/22744290

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High prevalence of B-RAF mutation in papillary carcinoma of the thyroid in north-east Italy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22744290

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Elements Related to Heterogeneity of Antibody-Dependent Cell Cytotoxicity in Patients Under Trastuzumab Therapy for Primary Operable Breast Cancer Overexpressing Her2

1 reference

https://pubmed.ncbi.nlm.nih.gov/22744290

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22744290

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women

1 reference

https://pubmed.ncbi.nlm.nih.gov/22744290

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00428-012-1267-2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22744290%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22744290%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44585456&oldid=2213627882"